UCLA Hematology/Oncology, 2020 Santa Monica Boulevard, Suite 600 - Site 042
Welcome,         Profile    Billing    Logout  
 4 Trials 
19 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rosen, Lee S
NCT04965818: Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

Terminated
1
38
US
Futibatinib and Binimetinib
Taiho Oncology, Inc.
Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer, KRAS Gene Mutation
06/23
09/23
NCT05395052: FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Terminated
1
5
US
FT536, NK Cell Therapy, Cyclophosphamide, Cy, Fludarabine, Flu, IL-2, Interleukin-2, Avelumab, Bavencio, Pembrolizumab, Keytruda, Nivolumab, Opdivo, Atezolizumab, Tecentriq, Trastuzumab, Herceptin, Cetuximab, Erbitux, Amivantamab, Rybrevant
Fate Therapeutics
Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
08/23
08/23
CX-5461-04, NCT04890613: Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Recruiting
1
52
Canada, US
CX-5461, Pidnarulex
Senhwa Biosciences, Inc.
Advanced Solid Tumor
12/24
06/25
RGX-202-001, NCT03597581: A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

Recruiting
1
108
US
ompenaclid, RGX-202-01, FOLFIRI, Bevacizumab, FOLFOX regimen
Inspirna, Inc.
Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Gastric Cancer, Gastric Neoplasm, KRAS Mutation-Related Tumors, CRC, Colorectal Cancer Metastatic
12/24
12/24
STAR, NCT04053283: First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector

Active, not recruiting
1
186
US
NG-641
Akamis Bio
Metastatic Cancer, Epithelial Tumor
08/24
12/24
NEBULA, NCT05043714: Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours

Checkmark Initiation of trial in combination with NG-641
Sep 2021 - Sep 2021: Initiation of trial in combination with NG-641
Active, not recruiting
1
30
Europe, US
NG-641 in combination with Nivolumab
Akamis Bio, Bristol-Myers Squibb
Metastatic Cancer, Epithelial Tumor
08/24
12/24
FORTIFY, NCT05165433: Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours

Active, not recruiting
1
198
Europe, US
NG-350A plus Pembrolizumab, KEYTRUDA®
Akamis Bio, Merck Sharp & Dohme LLC
Epithelial Tumor, Metastatic Cancer
03/25
05/25
NCT05948865: A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

Recruiting
1
102
Canada, US
CPO301, SYS6010
Conjupro Biotherapeutics, Inc.
Cancer, Cancer, Lung
06/25
12/25
NCT04242147: A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors

Terminated
1
45
US
KD033 (SAR445710)
Kadmon, a Sanofi Company
Solid Tumor
12/23
12/23
TORL4500-001, NCT06005740: A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer

Recruiting
1
70
Canada, US
TORL-4-500
TORL Biotherapeutics, LLC, Translational Research in Oncology
Advanced Solid Tumor, Hepatocellular Carcinoma
10/25
10/26
NCT04507503: Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Approved for marketing
N/A
US
TAS-120, Futibatinib
Taiho Oncology, Inc.
Advanced Cholangiocarcinoma
 
 
Lim, Christopher
KEYNOTE-E67, NCT05708950: A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

Recruiting
1/2
314
US
KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, Keytruda, KVA12123 - Dose Expansion, KVA12123 Plus Pembrolizumab - Dose Expansion
Kineta Inc., Merck Sharp & Dohme LLC
Cancer, Solid Tumor, Melanoma, Carcinoma, Sarcoma, Lung Cancer, Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Uterine Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Thyroid Cancer, Ovarian Cancer, Kidney Cancer, Head and Neck Cancer
06/24
12/24
NCT04965818: Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

Terminated
1
38
US
Futibatinib and Binimetinib
Taiho Oncology, Inc.
Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer, KRAS Gene Mutation
06/23
09/23
NCT05395052: FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Terminated
1
5
US
FT536, NK Cell Therapy, Cyclophosphamide, Cy, Fludarabine, Flu, IL-2, Interleukin-2, Avelumab, Bavencio, Pembrolizumab, Keytruda, Nivolumab, Opdivo, Atezolizumab, Tecentriq, Trastuzumab, Herceptin, Cetuximab, Erbitux, Amivantamab, Rybrevant
Fate Therapeutics
Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
08/23
08/23
NCT04064359: Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

Recruiting
1
200
Europe, US
OBT076, a CD205-directed antibody-drug conjugate, MEN1309
Oxford BioTherapeutics Ltd
Solid Tumor
12/26
12/27
CPO-100-US-101, NCT04931823: Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors

Active, not recruiting
1
126
US
CPO-100, DTX-HSA
Conjupro Biotherapeutics, Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Solid Tumor
03/25
03/25
FORTIFY, NCT05165433: Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours

Active, not recruiting
1
198
Europe, US
NG-350A plus Pembrolizumab, KEYTRUDA®
Akamis Bio, Merck Sharp & Dohme LLC
Epithelial Tumor, Metastatic Cancer
03/25
05/25
NCT04242147: A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors

Terminated
1
45
US
KD033 (SAR445710)
Kadmon, a Sanofi Company
Solid Tumor
12/23
12/23
FIT-001, NCT06026410: KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Recruiting
1
270
US
KO-2806, Cabozantinib, Cabometyx, Adagrasib, Krazati
Kura Oncology, Inc., Mirati Therapeutics Inc.
Solid Tumors with HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Clear Cell Renal Cell Carcinoma (ccRCC), Renal Cell Carcinoma (Kidney Cancer)
01/27
04/27

Download Options